Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-4945 in Recurrent SHH Medulloblastoma
NCT03904862Phase 2Terminated
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Jul 2019
- Primary completion
- Aug 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of silmitasertib in medulloblastoma (3 arms), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities at 4 weeks, Maximum Tolerated Dose or Recommended Phase 2 Dose of CX-4945 in Skeletally Immature Patients at 4 weeks and 3 more. Started Jul 2019; status: terminated.
02
Drugs
silmitasertib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT03904862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904862.